Greenland Mines Ltd. Common Stock (NASDAQ:GRML – Get Free Report) CFO Jeff Leblanc bought 14,000 shares of the company’s stock in a transaction on Tuesday, August 25th. The stock was purchased at an average cost of $9.72 per share, with a total value of $136,080.00. Following the completion of the transaction, the chief financial officer owned 110,406 shares in the company, valued at $1,073,146.32. This represents a 14.52% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Greenland Mines Ltd. Common Stock Stock Performance
Shares of GRML traded up $2.65 during mid-day trading on Tuesday, hitting $11.20. 1,605,544 shares of the company’s stock were exchanged, compared to its average volume of 102,120. The stock’s 50-day moving average is $0.39 and its 200-day moving average is $0.41. Greenland Mines Ltd. Common Stock has a fifty-two week low of $7.81 and a fifty-two week high of $39.45. The company has a market cap of $1.78 billion, a price-to-earnings ratio of -35.00 and a beta of 7.13.
Greenland Mines Ltd. Common Stock (NASDAQ:GRML – Get Free Report) last announced its quarterly earnings data on Monday, August 17th. The company reported ($1.50) earnings per share for the quarter.
Hedge Funds Weigh In On Greenland Mines Ltd. Common Stock
Wall Street Analysts Forecast Growth
A number of research firms recently issued reports on GRML. Weiss Ratings lowered Greenland Mines Ltd. Common Stock from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, August 11th. Wall Street Zen raised Greenland Mines Ltd. Common Stock to a “sell” rating in a research report on Saturday, May 2nd. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has a consensus rating of “Sell”.
View Our Latest Stock Report on GRML
About Greenland Mines Ltd. Common Stock
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases – cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.
Read More
- Five stocks we like better than Greenland Mines Ltd. Common Stock
- IBM Just Opened Its Mainframes to Arm—Is the Market Missing the Shift?
- Berkshire Boosts Its Bet: This AI Hyperscaler Is Now a Top-3 Holding
- NVIDIA Reveals $21 Billion SpaceX Stake: Signal of Confidence or Circular Financing?
- NVIDIA Earnings Could Move These 3 AI Stocks—Here’s What to Watch
Receive News & Ratings for Greenland Mines Ltd. Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenland Mines Ltd. Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.
